|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
54,830,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
161,290 |
4,952,633 |
Total Buy Value |
$0 |
$0 |
$4,999,990 |
$42,324,664 |
Total People Bought |
0 |
0 |
1 |
8 |
Total Buy Transactions |
0 |
0 |
1 |
26 |
Total Shares Sold |
92,517 |
247,545 |
2,132,004 |
2,207,972 |
Total Sell Value |
$3,561,659 |
$9,784,376 |
$62,783,959 |
$64,248,783 |
Total People Sold |
2 |
4 |
6 |
8 |
Total Sell Transactions |
7 |
12 |
16 |
29 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sofinnova Management X-A, L.l.c. |
10% Owner |
|
2023-02-06 |
4 |
B |
$7.00 |
$1,999,998 |
D/D |
285,714 |
3,467,156 |
2.45 |
- |
|
Enright Patrick G |
Director |
|
2023-02-06 |
4 |
B |
$7.00 |
$11,999,995 |
I/I |
1,714,285 |
1,714,285 |
2.25 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-03 |
4 |
B |
$7.24 |
$334,220 |
I/I |
46,163 |
1,389,315 |
2.1 |
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-16 |
4 |
AS |
$19.12 |
$43,116 |
D/D |
(2,212) |
26,821 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-16 |
4 |
OE |
$2.90 |
$6,408 |
D/D |
2,212 |
27,604 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-13 |
4 |
AS |
$18.19 |
$234,049 |
D/D |
(12,811) |
26,821 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-13 |
4 |
OE |
$6.37 |
$135,933 |
D/D |
12,811 |
27,899 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-12 |
4 |
AS |
$18.25 |
$125,924 |
D/D |
(6,900) |
26,821 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-12 |
4 |
OE |
$11.00 |
$75,900 |
D/D |
6,900 |
33,721 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-12-07 |
4 |
AS |
$16.47 |
$8,136 |
D/D |
(494) |
26,821 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-11-17 |
4 |
AS |
$15.84 |
$52,128 |
D/D |
(3,289) |
27,315 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-11-17 |
4 |
OE |
$2.90 |
$13,275 |
D/D |
3,289 |
29,526 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2022-11-16 |
4 |
OE |
$2.32 |
$185,750 |
D/D |
65,153 |
246,303 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-11-09 |
4 |
AS |
$16.54 |
$8,171 |
D/D |
(494) |
27,315 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-10-18 |
4 |
AS |
$19.39 |
$166,735 |
D/D |
(8,590) |
27,809 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-10-18 |
4 |
OE |
$2.90 |
$71,578 |
D/D |
8,590 |
27,811 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-10-05 |
4 |
AS |
$21.64 |
$21,380 |
D/D |
(988) |
27,809 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2022-10-04 |
4 |
AS |
$20.29 |
$386,065 |
D/D |
(18,223) |
181,150 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2022-10-04 |
4 |
OE |
$2.90 |
$52,788 |
D/D |
18,223 |
182,056 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2022-10-03 |
4 |
AS |
$20.39 |
$282,708 |
D/D |
(13,777) |
181,150 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2022-10-03 |
4 |
OE |
$2.90 |
$39,909 |
D/D |
13,777 |
183,558 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-09-21 |
4 |
AS |
$21.13 |
$25,124 |
D/D |
(1,174) |
28,797 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-09-21 |
4 |
OE |
$11.00 |
$12,914 |
D/D |
1,174 |
29,061 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-09-20 |
4 |
AS |
$20.24 |
$323,820 |
D/D |
(15,666) |
28,797 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2022-09-20 |
4 |
OE |
$2.90 |
$149,819 |
D/D |
15,666 |
38,909 |
|
- |
|
138 Records found
|
|
Page 3 of 6 |
|
|